Acute lung injury
Therapeutic area
Pulmonology
Rare disease
Yes
- Definition
- A condition of lung damage that is characterized by bilateral pulmonary infiltrates (pulmonary edema) rich in neutrophils, and in the absence of clinical heart failure. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Acute lung injury
- Alternative names
- acute lung injury
- Therapeutic area
- Pulmonology
- All therapeutic areas
- Pulmonology
- Severity
- Severe
- MONDO ID
- MONDO:0015796
- Parent condition
- MONDO:0005275
Related records
Broader conditions (8)
- Acute disease
- Disease
- Disease by body system or component
- Human disease
- Injury
- Lower respiratory tract disorder
- Lung disorder
- Respiratory system disorder
Trials (377)
- A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)
- A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury
- A Pilot Study Using Placenta Derived Decidual Stromal Cells for Toxicity and Inflammation With Special Focus to the Allogeneic Hematopoietic Cell Transplantation Setting
- A Real World Study of Respiratory Critical Disease.
- A Reverification of the Berlin Definition Plateau Criteria in Golmud
- A Single Dose, Dose Escalation Clinical Trial on the Safety, Tolerability and Efficacy of Lyophilized Powder for Inhalation of Recombinant Human Keratinocyte Growth Factor-2 (Rh-KGF-2) in The Treatment of Patients With Acute Respiratory Distress Syndrome
- a Study Conducted About a New Mode of Ventilation in Laparoscopic Surgeries
- A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
- A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure
- A Study on the Treatment of Patients With Acute Lung Injury Caused by Sepsis Through Microbiota Transplantation
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Intravenous Infusion of GW328267X in Healthy Volunteers
- A Study to Investigate the Effects of Imatinib on Pulmonary Vascular Dysfunction in a Human Model of Lung Injury
- A Trial to Evaluate the Impact of Lung-protective Intervention in Patients Undergoing Esophageal Cancer Surgery
- Acute CorPulmonale and ARDS Circulation Protection China Study China (ACPC)
- Acute Lung Injury After Allogeneic Transplantation - Diagnosis and Early Treatment
- Acute Lung Injury After Cardiac Surgery: Pathogenesis
- Acute Lung Injury in Children: Epidemiology and Natural History. PEDIATRIC ALIEN.
- Acute Lung Injury Ventilator Evaluation (ALIVE)
- Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation
- Adrecizumab (HAM8101) to Improve Prognosis and Outcomes in COVID-19 Trial
Drugs in development (28)
- Acetylcysteine Phase 2
- Ascorbic acid Phase 2
- Aspirin Phase 2
- Aviptadil Phase 2
- Calfactant Phase 2
- Daxdilimab Phase 1
- Depelestat Phase 2
- Dilmapimod Phase 2
- Dobutamine Phase 2
- Epinephrine Phase 2
- Furosemide Phase 2
- GSK-2586881 Phase 2
- GW-328267 Phase 1
- Heparin Phase 3
- Imatinib Phase 1
- L-citrulline Phase 3
- Lactose, anhydrous Phase 2
- Nezulcitinib Phase 1
- Norepinephrine Phase 2
- Phenylephrine Phase 2
Other linked drugs (4)
- Ivacaftor
- Lumacaftor
- Tezacaftor
- Xenon